Viromed Medical AG, DE000A3MQR65

Viromed Medical AG / DE000A3MQR65

29.11.2024 - 15:06:21

Viromed Medical AG will not acquire ActivCell Group AG and is focusing on another strategic option with greater added value

EQS-Ad-hoc: Viromed Medical AG / Key word(s): Mergers & Acquisitions


29-Nov-2024 / 15:06 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Pinneberg, 29 November 2024 – Viromed Medical AG (Ticker: VMED; ISIN: DE000A3MQR65; “Viromed”; the “Company”) has terminated negotiations for the planned acquisition of all shares in ActivCell Group AG, Switzerland, and will not pursue this opportunity further. On 17 September, Viromed had originally announced its intention to acquire 100% of ActivCell Group AG. The purchase price for this was to be in the mid-single-digit million euro range and was to be paid exclusively by granting new shares in the company, making partial use of the authorized capital 2022, in the context of a capital increase against contributions in kind, excluding shareholders' subscription rights. In the course of further negotiations, Viromed's management board has come to the conclusion that the added value of the proposed transaction in relation to the purchase price does not meet the company's expectations. Therefore, the negotiations will not be continued. Viromed Medical AG already has its own device, ViroCAP, which is by far the most advanced and innovative model in this field. The company has already made significant progress in the MDR 2a approval process with this device and is now focusing on bringing it to market on a broad scale.   Contact Viromed Medical AG Uwe Perbandt
CEO
Flensburger Strasse 18
25421 Pinneberg
Germany
Email: kontakt@viromed-medical.de
www.viromed-medical-ag.de


End of Inside Information

29-Nov-2024 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Viromed Medical AG
Flensburger Straße 18
25421 Pinneberg
Germany
Phone: +49 4101 809960
E-mail: kontakt@viromed-medical.de
Internet: https://www.viromed-medical-ag.de/
ISIN: DE000A3MQR65
WKN: A3MQR6
Listed: Regulated Unofficial Market in Berlin, Dusseldorf (Primärmarkt), Frankfurt (Basic Board), Hamburg
EQS News ID: 2041445

 
End of Announcement EQS News Service

2041445  29-Nov-2024 CET/CEST
fncls.ssp?fn=show_t_gif&application_id=2041445&application_name=news&site_id=trading_house_net~~~7efceac5-959a-43d6-afef-21ad42b6a5d4
@ dgap.de

Weitere Meldungen

EQS-News: Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH (deutsch) Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH EQS-News: Viromed Medical AG / Schlagwort(e): Kooperation Viromed Medical AG: Kooperation zwischen relyon plasma GmbH und Viromed Medical GmbH 05.12.2024 / 12:10 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. (Boerse, 05.12.2024 - 12:10) weiterlesen...

EQS-News: Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen (deutsch) Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen EQS-News: Viromed Medical AG / Schlagwort(e): Personalie Viromed Medical AG erweitert Vorstand - Christian Strauch als neues Vorstandsmitglied berufen 03.12.2024 / 15:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. (Boerse, 03.12.2024 - 15:00) weiterlesen...

EQS-Adhoc: Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts (deutsch) Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts EQS-Ad-hoc: Viromed Medical AG / Schlagwort(e): Fusionen & Übernahmen Viromed Medical AG plant Erwerb sämtlicher Anteile an der pharmedix GmbH durch Kapitalerhöhung gegen Sacheinlage unter Ausschluss des Bezugsrechts 03.12.2024 / 13:53 CET/CEST Veröffentlichung einer Insiderinformation nach Artikel 17 der Verordnung (EU) Nr. (Boerse, 03.12.2024 - 13:53) weiterlesen...